登陆
当前位置: 首页 >> 检索结果

结果排序

文献格式

出版时间

出版类型

出版语言
共有 4693 条符合本次的查询结果， 用时 1.1892075 秒

3921. Githinji Gitahi: advocating for universal health coverage in Africa.

作者: Udani Samarasekera.
来源: Lancet. 2023年402卷10397期175页

3922. New US$1·5 billion fund for primary care.

作者: Udani Samarasekera.
来源: Lancet. 2023年402卷10397期174页

3923. Kenya introduces huge school meals programme.

作者: Sharmila Devi.
来源: Lancet. 2023年402卷10397期173页

3924. 12 countries to get first doses of malaria vaccine.

作者: Sharmila Devi.
来源: Lancet. 2023年402卷10397期172页

3925. Lack of global leadership on nutrition "unforgivable".

作者: John Zarocostas.
来源: Lancet. 2023年402卷10397期171页

3926. Metaphyseal sclerosis in a child with a giant cell tumour treated with denosumab.

作者: Vivian Szymczuk.;Alison Boyce.;Nadia Merchant.
来源: Lancet. 2023年402卷10397期e4页

3927. Department of Error.

来源: Lancet. 2023年402卷10397期184页

3928. Machine learning-based markers for CAD - Authors' reply.

作者: Iain S Forrest.;Ben O Petrazzini.;Ron Do.
来源: Lancet. 2023年402卷10397期184页

3929. Machine learning-based markers for CAD.

作者: Justin Jee.
来源: Lancet. 2023年402卷10397期183页

3930. Machine learning-based markers for CAD.

作者: Amanda Elliott.;James P Pirruccello.
来源: Lancet. 2023年402卷10397期182-183页

3931. Machine learning-based markers for CAD.

作者: Linghua Yu.
来源: Lancet. 2023年402卷10397期182页

3932. The value of IMmotion010 for rare kidney cancer histologies.

作者: Giovanni Maria Iannantuono.;Elias Chandran.;Andrea B Apolo.
来源: Lancet. 2023年402卷10397期181页

3933. The value of IMmotion010 for rare kidney cancer histologies - Authors' reply.

作者: Robert Uzzo.;Axel Bex.;Sumanta K Pal.
来源: Lancet. 2023年402卷10397期181-182页

3934. Moravec's paradox and the fear of job automation in health care.

作者: Anmol Arora.
来源: Lancet. 2023年402卷10397期180-181页

3935. How to avoid causing polio in the name of its eradication.

作者: T Jacob John.;Dhanya Dharmapalan.;Norbert Hirschhorn.;Robert Steinglass.
来源: Lancet. 2023年402卷10397期179-180页

3936. Clearing the air for a sustainable future.

作者: The Lancet.
来源: Lancet. 2023年402卷10397期159页

3937. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.

作者: Jürgen C Becker.;Selma Ugurel.;Ulrike Leiter.;Friedegund Meier.;Ralf Gutzmer.;Sebastian Haferkamp.;Lisa Zimmer.;Elisabeth Livingstone.;Thomas K Eigentler.;Axel Hauschild.;Felix Kiecker.;Jessica C Hassel.;Peter Mohr.;Michael Fluck.;Ioannis Thomas.;Marlene Garzarolli.;Imke Grimmelmann.;Konstantin Drexler.;Alexandra N Spillner.;Sebastian Eckhardt.;Dirk Schadendorf.; .
来源: Lancet. 2023年402卷10404期798-808页
Merkel cell carcinoma (MCC) is an immunogenic but aggressive skin cancer. Even after complete resection and radiation, relapse rates are high. PD-1 and PD-L1 checkpoint inhibitors showed clinical benefit in advanced MCC. We aimed to assess efficacy and safety of adjuvant immune checkpoint inhibition in completely resected MCC (ie, a setting without an established systemic standard-of-care treatment).

3938. Should adjuvant nivolumab be used in surgically resected Merkel cell carcinoma patients?

作者: Philippe Saiag.;Astrid Blom.
来源: Lancet. 2023年402卷10404期751-753页

3939. EAT-Lancet Commission 2.0: securing a just transition to healthy, environmentally sustainable diets for all.

作者: .
来源: Lancet. 2023年402卷10399期352-354页

3940. Structural racism and iron deficiency anaemia.

作者: Ian Roberts.;Camara Phyllis Jones.
来源: Lancet. 2023年402卷10405期834-835页
共有 4693 条符合本次的查询结果， 用时 1.1892075 秒